News
Moderna’s new flu vaccine shows positive results in elderly individuals
Moderna’s latest flu vaccine, based on similar mRNA technology integrated in its COVID-19 shot, displayed optimistic outcomes in a significant trial.On Monday, the company revealed that the vaccine, which is known as mRNA-1010,
Moderna’s Promised mRNA Flu Vaccine Bests Current Standard Shot
In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the company pulled its application for a combo flu/COVID-19 shot, saying it would refile following data from this Phase III trial.
Zacks Investment Research on MSN7h
Moderna Stock Gains on Encouraging Flu Vaccine DataModerna MRNA announced that its seasonal influenza vaccine candidate, mRNA-1010, achieved superior relative vaccine efficacy ...
Moderna’s mRNA flu shot outperforms existing vaccines in Phase 3 trial, showing over 26% greater efficacy—paving the way for ...
Pharmalittle: We’re reading about a Moderna flu vaccine, a J&J loss over 340B rebate plans, and more
Moderna disclosed that a study of 56,000 volunteers older than 50 found its new mRNA flu vaccine was more effective than an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback